WO2008045419A1 - Preparation of nucleosides ribofuranosyl pyrimidines - Google Patents
Preparation of nucleosides ribofuranosyl pyrimidines Download PDFInfo
- Publication number
- WO2008045419A1 WO2008045419A1 PCT/US2007/021548 US2007021548W WO2008045419A1 WO 2008045419 A1 WO2008045419 A1 WO 2008045419A1 US 2007021548 W US2007021548 W US 2007021548W WO 2008045419 A1 WO2008045419 A1 WO 2008045419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- aryl
- methyl
- process according
- fluoro
- Prior art date
Links
- 0 C1CC*CC1 Chemical compound C1CC*CC1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020097008991A KR101057239B1 (en) | 2006-10-10 | 2007-10-05 | Preparation of Nucleoside Ribofuranosyl Pyrimidine |
BRPI0719174A BRPI0719174A2 (en) | 2006-10-10 | 2007-10-05 | preparation of ribofuranosyl nucleoside pyrimidines |
JP2009532372A JP5252459B2 (en) | 2006-10-10 | 2007-10-05 | Preparation of ribofuranosylpyrimidine nucleosides |
EP07839369.1A EP2084174B1 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
US12/444,608 US8912321B2 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
CN200780037855.XA CN101600725B (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
AU2007307057A AU2007307057B2 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
DK07839369.1T DK2084174T3 (en) | 2006-10-10 | 2007-10-05 | Preparation of ribofuranosylpyrimidine nucleotides |
PL07839369T PL2084174T3 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
ES07839369T ES2429290T3 (en) | 2006-10-10 | 2007-10-05 | Preparation of ribofuranosylpyrimidine nucleosides |
SI200731311T SI2084174T1 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
CA2666098A CA2666098C (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
MX2009003795A MX2009003795A (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines. |
IL198086A IL198086A (en) | 2006-10-10 | 2009-04-07 | Preparation of nucleosides ribofuranosyl pyrimidines |
HK10101126.3A HK1133889A1 (en) | 2006-10-10 | 2010-02-02 | Preparation of nucleosides ribofuranosyl pyrimidines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85096206P | 2006-10-10 | 2006-10-10 | |
US60/850,962 | 2006-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008045419A1 true WO2008045419A1 (en) | 2008-04-17 |
Family
ID=39111500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/021548 WO2008045419A1 (en) | 2006-10-10 | 2007-10-05 | Preparation of nucleosides ribofuranosyl pyrimidines |
Country Status (19)
Country | Link |
---|---|
US (2) | US8912321B2 (en) |
EP (1) | EP2084174B1 (en) |
JP (1) | JP5252459B2 (en) |
KR (1) | KR101057239B1 (en) |
CN (1) | CN101600725B (en) |
AU (1) | AU2007307057B2 (en) |
BR (1) | BRPI0719174A2 (en) |
CA (1) | CA2666098C (en) |
DK (1) | DK2084174T3 (en) |
ES (1) | ES2429290T3 (en) |
GT (1) | GT200900080A (en) |
HK (1) | HK1133889A1 (en) |
IL (1) | IL198086A (en) |
MX (1) | MX2009003795A (en) |
PL (1) | PL2084174T3 (en) |
PT (1) | PT2084174E (en) |
RU (1) | RU2421461C2 (en) |
SI (1) | SI2084174T1 (en) |
WO (1) | WO2008045419A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
WO2010135569A1 (en) | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production |
WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
WO2011152155A1 (en) | 2010-06-03 | 2011-12-08 | セントラル硝子株式会社 | Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-γ-lactone precursor |
EP2609923A2 (en) | 2010-03-31 | 2013-07-03 | Gilead Pharmasset LLC | Nucleoside Phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
US8580765B2 (en) | 2007-03-30 | 2013-11-12 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
WO2013178571A1 (en) | 2012-05-29 | 2013-12-05 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8759510B2 (en) | 2008-06-11 | 2014-06-24 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CN104610404A (en) * | 2015-01-16 | 2015-05-13 | 南通常佑药业科技有限公司 | Preparation method of ribofuranose phosphate derivative |
WO2016042576A1 (en) | 2014-09-16 | 2016-03-24 | Cadila Healthcare Limited | Co-crystal of sofosbuvir and amino acid and process for preparation thereof |
US9376410B2 (en) | 2012-10-10 | 2016-06-28 | Topharman Shanghai Co., Ltd. | (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US10039779B2 (en) | 2013-01-31 | 2018-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10239910B2 (en) | 2016-07-20 | 2019-03-26 | Optimus Drugs (P) Limited | Process for the preparation of sofosbuvir |
US11116783B2 (en) | 2013-08-27 | 2021-09-14 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1576138B1 (en) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
ES2726998T3 (en) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogs |
PT3109244T (en) * | 2004-09-14 | 2019-06-04 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
KR101229942B1 (en) | 2004-11-16 | 2013-02-06 | 톰슨 라이센싱 | Film grain sei message insertion for bit-accurate simulation in a video system |
ATE553455T1 (en) | 2004-11-16 | 2012-04-15 | Thomson Licensing | METHOD FOR SIMULATING FILM GRAIN BASED ON PRECALCULATED TRANSFORMATION COEFFICIENTS |
TR201911138T4 (en) | 2004-11-17 | 2019-08-21 | Interdigital Vc Holdings Inc | Bit-free film grain simulation method based on pre-computed transformed coefficients. |
US10715834B2 (en) | 2007-05-10 | 2020-07-14 | Interdigital Vc Holdings, Inc. | Film grain simulation based on pre-computed transform coefficients |
EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
EA201490836A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EA027929B1 (en) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Uracyl spirooxetane nucleosides |
CN103450148B (en) * | 2012-06-04 | 2018-06-12 | 浙江九洲药业股份有限公司 | A kind of synthetic method of five-membered ring sulfate compound |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
ES2674980T3 (en) | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | 2'-chloro nucleoside analogs for HCV infection |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
CN103012386B (en) * | 2012-12-26 | 2015-04-01 | 浙江普洛得邦制药有限公司 | Preparation method of five-membered cyclic sulphate |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
CN104447923B (en) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | Methyl nucleoside derivatives of 2 ' deoxidation, 2 ' fluorine 2 ' and preparation method thereof and the purposes in pharmacy |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
CN104744539A (en) * | 2014-09-19 | 2015-07-01 | 上海皓元生物医药科技有限公司 | Synthesis method for (2'R)-2'-deoxy-2'-fluorine-2'-methyl uridine |
CN104327138B (en) * | 2014-10-21 | 2017-05-10 | 齐鲁制药有限公司 | Preparation method of PSI-7977 intermediate compound |
UA124966C2 (en) | 2015-03-06 | 2021-12-22 | Атеа Фармасеутікалс, Інк. | <font face="Symbol">b</font>-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N<sup>6</sup>-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
CN104829672B (en) * | 2015-05-19 | 2018-03-13 | 江苏福瑞生物医药有限公司 | A kind of synthetic method of pharmaceutical intermediate |
CN105061535A (en) * | 2015-09-02 | 2015-11-18 | 江苏科本医药化学有限公司 | Synthetic method of sofosbuvir intermediate |
CN106554333B (en) * | 2015-09-29 | 2018-11-30 | 江苏福瑞生物医药有限公司 | A kind of synthetic method of pharmaceutical intermediate |
CN106608896B (en) * | 2015-10-26 | 2019-08-27 | 江苏福瑞康泰药业有限公司 | A kind of synthetic method of pharmaceutical intermediate |
CN105418547A (en) * | 2015-11-17 | 2016-03-23 | 海门慧聚药业有限公司 | Preparation for sofosbuvir key intermediate |
CN105503983B (en) * | 2015-12-17 | 2019-06-28 | 江苏阿尔法药业有限公司 | The preparation method of Suo Feibuwei intermediate and its derivative |
CN105566422B (en) * | 2015-12-29 | 2019-06-25 | 江苏阿尔法药业有限公司 | The preparation method of Suo Feibuwei intermediate or derivatives thereof |
CN109689063A (en) | 2016-04-28 | 2019-04-26 | 埃默里大学 | Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
EP3865136A1 (en) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for corona virus treatment |
KR20230151050A (en) | 2017-02-01 | 2023-10-31 | 아테아 파마슈티컬즈, 인크. | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
CN106810515A (en) * | 2017-02-06 | 2017-06-09 | 抚州市星辰药业有限公司 | The midbody compound and its synthetic method of a kind of synthesis Suo Feibuwei |
CN109422789A (en) * | 2017-08-28 | 2019-03-05 | 常州制药厂有限公司 | A kind of preparation process amelioration method of Suo Feibuwei |
TW202012001A (en) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | Treatment of cirrhotic hcv infected patients |
CN108675984A (en) * | 2018-06-22 | 2018-10-19 | 江苏阿尔法药业有限公司 | The preparation method of Suo Feibuwei intermediates |
CN111606961A (en) * | 2019-02-26 | 2020-09-01 | 顾世海 | Process production method of (2 'R) -2' -deoxy-2 '-fluoro-2' -methyluridine |
CN111040010A (en) * | 2019-12-23 | 2020-04-21 | 上海红蓝医药科技有限公司 | Synthetic method of sofosbuvir intermediate |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136693A2 (en) * | 1983-10-03 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Production of cytidine derivatives |
US20050009737A1 (en) * | 2003-05-30 | 2005-01-13 | Jeremy Clark | Modified fluorinated nucleoside analogues |
WO2006012440A2 (en) * | 2004-07-21 | 2006-02-02 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
WO2006031725A2 (en) * | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE344271T1 (en) | 1998-02-25 | 2006-11-15 | Univ Emory | 2'-FLUORONUCLEOSIDES |
IL147757A0 (en) | 1999-07-30 | 2002-08-14 | Abbott Gmbh & Co Kg | 2-pyrazolin-5-ones |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (en) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | APPLICATION OF RIBONOUSALIC COMPOUNDS FOR TREATING FLAVIVIRUS AND PESTIVIRUS INFECTIONS |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
JP2005504087A (en) | 2001-09-28 | 2005-02-10 | イデニクス(ケイマン)リミテツド | Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
BR0312278A (en) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections |
JP2005533817A (en) | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | Modified 2 'and 3'-nucleoside prodrugs for the treatment of Flaviviridae virus infection |
EP1576138B1 (en) | 2002-11-15 | 2017-02-01 | Idenix Pharmaceuticals LLC. | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
BRPI0412849A (en) | 2003-07-25 | 2006-09-26 | Idenix Cayman Ltd | compounds, compositions and uses of purine nucleoside analogues for the treatment of flaviviridae, including hepatitis c |
JP2007504152A (en) | 2003-08-27 | 2007-03-01 | ビオタ, インコーポレイテッド | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
CA2565013C (en) * | 2004-04-30 | 2013-01-08 | Daiichi Pharmaceutical Co., Ltd. | Method for producing pentacyclic taxans |
-
2007
- 2007-10-05 CA CA2666098A patent/CA2666098C/en active Active
- 2007-10-05 PL PL07839369T patent/PL2084174T3/en unknown
- 2007-10-05 EP EP07839369.1A patent/EP2084174B1/en active Active
- 2007-10-05 ES ES07839369T patent/ES2429290T3/en active Active
- 2007-10-05 SI SI200731311T patent/SI2084174T1/en unknown
- 2007-10-05 JP JP2009532372A patent/JP5252459B2/en active Active
- 2007-10-05 CN CN200780037855.XA patent/CN101600725B/en active Active
- 2007-10-05 AU AU2007307057A patent/AU2007307057B2/en active Active
- 2007-10-05 US US12/444,608 patent/US8912321B2/en active Active
- 2007-10-05 BR BRPI0719174A patent/BRPI0719174A2/en not_active IP Right Cessation
- 2007-10-05 PT PT78393691T patent/PT2084174E/en unknown
- 2007-10-05 WO PCT/US2007/021548 patent/WO2008045419A1/en active Application Filing
- 2007-10-05 RU RU2009117396/04A patent/RU2421461C2/en not_active IP Right Cessation
- 2007-10-05 DK DK07839369.1T patent/DK2084174T3/en active
- 2007-10-05 KR KR1020097008991A patent/KR101057239B1/en active IP Right Grant
- 2007-10-05 MX MX2009003795A patent/MX2009003795A/en active IP Right Grant
- 2007-10-10 US US11/973,748 patent/US20080139802A1/en not_active Abandoned
-
2009
- 2009-04-07 IL IL198086A patent/IL198086A/en active IP Right Grant
- 2009-04-13 GT GT200900080A patent/GT200900080A/en unknown
-
2010
- 2010-02-02 HK HK10101126.3A patent/HK1133889A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136693A2 (en) * | 1983-10-03 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Production of cytidine derivatives |
US20050009737A1 (en) * | 2003-05-30 | 2005-01-13 | Jeremy Clark | Modified fluorinated nucleoside analogues |
WO2006012440A2 (en) * | 2004-07-21 | 2006-02-02 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
WO2006031725A2 (en) * | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
Non-Patent Citations (2)
Title |
---|
C. R. SCHMID; J. D. BRYANT; JERRY D., ORG. SYN., vol. 72, 1995, pages 6 - 13 |
HELMUT VORBRÜGGEN: "Adventures in Silicon-Organic Chemistry", ACCOUNTS OF CHEMICAL RESEARCH, vol. 28, 1995, pages 509 - 520, XP002471456 * |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580765B2 (en) | 2007-03-30 | 2013-11-12 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8735372B2 (en) | 2007-03-30 | 2014-05-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US11642361B2 (en) | 2007-03-30 | 2023-05-09 | Gilead Sciences, Inc. | Nucleoside phosphoramidate prodrugs |
US10183037B2 (en) | 2007-03-30 | 2019-01-22 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9585906B2 (en) | 2007-03-30 | 2017-03-07 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9085573B2 (en) | 2007-03-30 | 2015-07-21 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8906880B2 (en) | 2007-03-30 | 2014-12-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8759510B2 (en) | 2008-06-11 | 2014-06-24 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP3222628A1 (en) | 2008-12-23 | 2017-09-27 | Gilead Pharmasset LLC | Nucleoside phosphoramidates |
US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EA019295B1 (en) * | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Synthesis of purine nucleosides and process for preparing them |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8957045B2 (en) | 2008-12-23 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP2910562A1 (en) | 2009-05-20 | 2015-08-26 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2 '-fluoro-2'-methyl-p-phenyl-5 '-uridylyl]-l-alanine 1-methylethyl ester in crystalline form |
US8642756B2 (en) | 2009-05-20 | 2014-02-04 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8735569B2 (en) | 2009-05-20 | 2014-05-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8633309B2 (en) | 2009-05-20 | 2014-01-21 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8629263B2 (en) | 2009-05-20 | 2014-01-14 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
WO2010135569A1 (en) | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production |
EP3321275A1 (en) | 2009-05-20 | 2018-05-16 | Gilead Pharmasset LLC | Crystalline form of sofosbuvir |
US9637512B2 (en) | 2009-05-20 | 2017-05-02 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9284342B2 (en) | 2009-05-20 | 2016-03-15 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9206217B2 (en) | 2009-05-20 | 2015-12-08 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP2913337A1 (en) | 2009-05-20 | 2015-09-02 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production |
EP2610264A2 (en) | 2009-05-20 | 2013-07-03 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production |
EP3290428A1 (en) | 2010-03-31 | 2018-03-07 | Gilead Pharmasset LLC | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
EP2752422A1 (en) | 2010-03-31 | 2014-07-09 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
EP2609923A2 (en) | 2010-03-31 | 2013-07-03 | Gilead Pharmasset LLC | Nucleoside Phosphoramidates |
WO2011123645A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Nucleoside phosphoramidates |
US8859756B2 (en) | 2010-03-31 | 2014-10-14 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
WO2011152155A1 (en) | 2010-06-03 | 2011-12-08 | セントラル硝子株式会社 | Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-γ-lactone precursor |
JP2012144511A (en) * | 2010-06-03 | 2012-08-02 | Central Glass Co Ltd | METHOD FOR PRODUCING (2R)-2-FLUORO-2-C-METHYL-D-RIBONO-γ-LACTONE PRECURSOR |
US8669382B2 (en) | 2010-06-03 | 2014-03-11 | Central Glass Company, Limited | Method for producing (2R)-2-fluoro-2-C-methyl-D-ribono-γ-lactone precursor |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US10456414B2 (en) | 2011-09-16 | 2019-10-29 | Gilead Pharmasset Llc | Methods for treating HCV |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013178571A1 (en) | 2012-05-29 | 2013-12-05 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds |
US9376410B2 (en) | 2012-10-10 | 2016-06-28 | Topharman Shanghai Co., Ltd. | (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof |
US10039779B2 (en) | 2013-01-31 | 2018-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US11707479B2 (en) | 2013-08-27 | 2023-07-25 | Gilead Sciences, Inc. | Combination formulation of two antiviral compounds |
US11116783B2 (en) | 2013-08-27 | 2021-09-14 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
WO2016042576A1 (en) | 2014-09-16 | 2016-03-24 | Cadila Healthcare Limited | Co-crystal of sofosbuvir and amino acid and process for preparation thereof |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN104610404A (en) * | 2015-01-16 | 2015-05-13 | 南通常佑药业科技有限公司 | Preparation method of ribofuranose phosphate derivative |
WO2016112746A1 (en) * | 2015-01-16 | 2016-07-21 | 南通常佑药业科技有限公司 | Method for preparing ribofuranose phosphate derivatives |
US10239910B2 (en) | 2016-07-20 | 2019-03-26 | Optimus Drugs (P) Limited | Process for the preparation of sofosbuvir |
Also Published As
Publication number | Publication date |
---|---|
US8912321B2 (en) | 2014-12-16 |
PL2084174T3 (en) | 2013-12-31 |
GT200900080A (en) | 2012-04-10 |
RU2009117396A (en) | 2010-11-20 |
BRPI0719174A2 (en) | 2017-06-13 |
US20080139802A1 (en) | 2008-06-12 |
EP2084174A1 (en) | 2009-08-05 |
JP2010505954A (en) | 2010-02-25 |
CA2666098C (en) | 2012-09-25 |
CA2666098A1 (en) | 2008-04-17 |
MX2009003795A (en) | 2009-06-18 |
JP5252459B2 (en) | 2013-07-31 |
KR20090060460A (en) | 2009-06-12 |
SI2084174T1 (en) | 2013-10-30 |
EP2084174B1 (en) | 2013-07-31 |
ES2429290T3 (en) | 2013-11-14 |
CN101600725B (en) | 2014-11-26 |
AU2007307057B2 (en) | 2011-09-15 |
AU2007307057A1 (en) | 2008-04-17 |
DK2084174T3 (en) | 2013-11-04 |
PT2084174E (en) | 2013-10-08 |
US20100056770A1 (en) | 2010-03-04 |
CN101600725A (en) | 2009-12-09 |
KR101057239B1 (en) | 2011-08-16 |
IL198086A0 (en) | 2009-12-24 |
IL198086A (en) | 2012-03-29 |
HK1133889A1 (en) | 2010-04-09 |
RU2421461C2 (en) | 2011-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2084174B1 (en) | Preparation of nucleosides ribofuranosyl pyrimidines | |
Mansuri et al. | Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV | |
JP2010505954A5 (en) | ||
EP2855497B1 (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
WO1988007532A1 (en) | 2',3' dideoxyribofuranoxide derivatives | |
IL176075A (en) | Process for producing fluorocytidine derivatives and some such compounds | |
JP5766703B2 (en) | Synthesis of decitabine | |
EP0193903A2 (en) | Production of cytosine nucleosides | |
CN1137892C (en) | Preparation of N-9 substituted guanine compound | |
JP5550234B2 (en) | Method for producing furanose derivatives | |
JP2009526782A (en) | Method for producing gemcitabine and related intermediates | |
US6933382B2 (en) | Process for the synthesis of 2-deoxy-D-glucose | |
WO2007070804A2 (en) | Process for preparing gemcitabine and associated intermediates | |
US6897302B2 (en) | Method for synthesizing β-L-5-fluoro-2′,3′-dideoxy-2′,3′-didehydrocytidine (β-L-FD4C) | |
Richardson et al. | Synthesis and properties of psico-nucleosides | |
EP1960378A1 (en) | A manufacturing process of 2',2'-difluoronucleoside and intermediate | |
Maougal et al. | Synthesis of conformationally constrained nucleoside analogues | |
TĂNASE et al. | A NEW WAY TO NUCLEOSIDES WITH AN OXABICYCLO [3.3. 0] OCTANE SCAFFOLD FROM AN ADVANCED INTERMEDIATE IN THE SYNTHESIS OF THE PROSTAGLANDIN ANALOG, CLOPROSTENOL | |
WO2008026222A2 (en) | Process and intermediates of 2,2' difluoronucleosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780037855.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07839369 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007307057 Country of ref document: AU Ref document number: 198086 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2666098 Country of ref document: CA Ref document number: MX/A/2009/003795 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009532372 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 817/MUMNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097008991 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007307057 Country of ref document: AU Date of ref document: 20071005 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007839369 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009117396 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12444608 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0719174 Country of ref document: BR Free format text: REGULARIZE O DOCUMENTO DE CESSAO DO DIREITO DE PRIORIDADE REFERENTE A PRIORIDADE "US 60/850,962" DE 10/10/2006, QUE FOI APRESENTADO NA PETICAO NO. 020090056698 DE 08/06/2009, APRESENTANDO A CESSAO DO DIREITO DE PRIORIDADE DOS INVENTORES/DEPOSITANTES DA PRIORIDADE "US 60/850,962" DE 10/10/2006 ("STEVEN D. AXT", "KESHAB SARMA", "JUSTIN VITALE", "JIANG ZHU" E "QINGWU JIN") PARA O DEPOSITANTE "PHARMASSET, INC." E DOS INVENTORES/DEPOSITANTES DA PRIORIDADE "US 60/850,962" DE 10/10/2006 ("BRUCE ROSS", 'SUGUNA RACHAKONDA" E "BYOUNG-KWON CHU") PARA O DEPOSITANTE "F. HOFFMANN-LA ROCHE AG". |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0719174 Country of ref document: BR Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2257 DE 08/04/2014, PARA QUE POSSA SER ACEITO A COPIA DO DOCUMENTO DE PRIORIDADE DISPONIVEL NA FASE INTERNACIONAL COMO UM DOCUMENTO DE CESSAO DOS DIREITOS DA PRIORIDADE, APRESENTE DOCUMENTOS QUE COMPROVEM A ALTERACAO DE NOME DO DEPOSITANTE "ROCHE PALO ALTO LLC" PARA "F. HOFFMANN LA-ROCHE AG". |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: PI0719174 Country of ref document: BR Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: PI0719174 Country of ref document: BR Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0719174 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090409 |